![](jpg/adobestock_418911722-768x432.jpg)
STAT Plus: What to know about Alnylam’s upcoming readout on its heart drug
Results of Alnylam’s HELIOS-B trial could affect care — and impact stock price of Pfizer and BridgeBio, which offer competing therapies.
Cancel anytime.
Subscribe nowOur Picks
Our Picks
a stat investigation
a stat investigation